|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 222.99 USD | -0.06% |
|
-0.94% | +25.49% |
| 08/12 | OSE Immunotherapeutics Amends Partnership With AbbVie for Inflammation Drug Development | MT |
| 08/12 | OSE Immunotherapeutics Amends Partnership Agreement with AbbVie on ABBV-230 |  |
| Capitalization | 39TCr 34TCr 32TCr 30TCr 55TCr 35,43500Cr 59TCr 3,68600Cr 1,43200Cr 16,79600Cr 1,48000Cr 1,44800Cr 61,85200Cr | P/E ratio 2025 * |
52.1x | P/E ratio 2026 * | 22.9x |
|---|---|---|---|---|---|
| Enterprise value | 45TCr 39TCr 36TCr 34TCr 62TCr 40,46900Cr 68TCr 4,21000Cr 1,63600Cr 19,18200Cr 1,69000Cr 1,65400Cr 70,63900Cr | EV / Sales 2025 * |
7.39x | EV / Sales 2026 * | 6.62x |
| Free-Float |
96.39% | Yield 2025 * |
2.92% | Yield 2026 * | 3.04% |
Last Transcript: AbbVie Inc.
| 1 day | -0.06% | ||
| 1 week | -0.94% | ||
| Current month | -2.07% | ||
| 1 month | +1.75% | ||
| 3 months | +6.29% | ||
| 6 months | +17.47% | ||
| Current year | +25.49% |
| 1 week | 220.23 |  | 230.94 |
| 1 month | 216.15 | | 239.29 |
| Current year | 164.39 | | 244.81 |
| 1 year | 164.39 | | 244.81 |
| 3 years | 130.96 | | 244.81 |
| 5 years | 101.55 | | 244.81 |
| 10 years | 50.71 | | 244.81 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 54 | 01/07/2024 |
Scott Reents
DFI | Director of Finance/CFO | 58 | 23/06/2022 |
Roopal Thakkar
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2003 |
| Director | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 64 | 01/01/2013 |
William Burnside
BRD | Director/Board Member | 73 | 01/01/2013 |
Edward Rapp
BRD | Director/Board Member | 67 | 01/01/2013 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 7.12% | 6 M€ | 0.00% | - |
| 6.85% | 26 M€ | +11.55% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.06% | -0.94% | +26.56% | +34.34% | 39TCr | |
| -1.54% | -6.11% | +22.23% | +172.09% | 89TCr | |
| -0.82% | -2.66% | +33.66% | +13.78% | 49TCr | |
| -0.76% | +2.04% | +22.68% | +4.08% | 34TCr | |
| +0.10% | -1.76% | +27.58% | +20.11% | 28TCr | |
| +0.17% | +2.46% | +18.94% | +25.23% | 25TCr | |
| -2.06% | -4.10% | -6.65% | -10.93% | 25TCr | |
| +0.07% | -4.85% | -61.91% | -33.31% | 21TCr | |
| -2.30% | -7.24% | +13.05% | +12.63% | 17TCr | |
| -1.51% | -3.67% | +31.76% | +35.68% | 15TCr | |
| Average | -0.15% | -2.03% | +12.79% | +27.37% | 34.19TCr | |
| Weighted average by Cap. | +0.19% | -2.41% | +17.39% | +54.21% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 6.09TCr 5.24TCr 4.91TCr 4.58TCr 8.44TCr 5,47500Cr 9.18TCr 57TCr 22TCr 2,59500Cr 23TCr 22TCr 9,55700Cr | 6.66TCr 5.73TCr 5.37TCr 5.01TCr 9.22TCr 5,98600Cr 10TCr 62TCr 24TCr 2,83700Cr 25TCr 24TCr 10,44900Cr |
| Net income | 909.83Cr 782.56Cr 733.43Cr 684.06Cr 1.26TCr 82TCr 1.37TCr 8.5TCr 3.3TCr 39TCr 3.41TCr 3.34TCr 1,42700Cr | 1.74TCr 1.5TCr 1.4TCr 1.31TCr 2.41TCr 1,56600Cr 2.63TCr 16TCr 6.33TCr 74TCr 6.54TCr 6.4TCr 2,73400Cr |
| Net Debt | 5.6TCr 4.82TCr 4.52TCr 4.21TCr 7.76TCr 5,03400Cr 8.44TCr 52TCr 20TCr 2,38600Cr 21TCr 21TCr 8,78700Cr | 4.65TCr 4TCr 3.75TCr 3.49TCr 6.44TCr 4,17600Cr 7TCr 43TCr 17TCr 1,97900Cr 17TCr 17TCr 7,28900Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/25/09 | 222.99 $ | -0.06% | 42,47,837 |
| 08/25/08 | 223.12 $ | -1.31% | 40,06,095 |
| 05/25/05 | 226.08 $ | -1.15% | 39,85,199 |
| 04/25/04 | 228.71 $ | -0.66% | 37,33,100 |
| 03/25/03 | 230.24 $ | +2.62% | 48,73,263 |
Delayed Quote Nyse, December 10, 2025 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABBV Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition